Truncated androgen receptor splice variants in prostate cancer

Peter E. Lonergan, Donald J. Tindall

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

The androgen receptor (AR) is fundamental for the growth and survival of normal and malignant prostate cells. Therefore, androgen deprivation therapy remains the first-line treatment for disseminated disease; however, relapse and progression to a castration-resistant phenotype for which no durable treatment currently exists, is inevitable. Restored AR activity is fundamental in the progression to castration-resistant prostate cancer. Multiple mechanisms by which AR is reactivated under androgen- depleted conditions may be involved in the development of this lethal phenotype. Recent studies have identified alternatively spliced transcripts encoding truncated AR isoforms that lack the ligand-binding domain, which is the therapeutic target of androgen deprivation therapy. Many of these truncated AR variants function as constitutively active, ligand-independent transcription factors that can support androgenindependent expression of AR target genes, as well as ligand-independent growth of prostate cancer cells. In this chapter, we will summarize the recent developments in the identification and characterization of AR splice variants in prostate cancer.

Original languageEnglish (US)
Title of host publicationProstate Cancer
Subtitle of host publicationBiochemistry, Molecular Biology and Genetics
PublisherSpringer New York
Pages351-382
Number of pages32
ISBN (Electronic)9781461468288
ISBN (Print)9781461468271
DOIs
StatePublished - Jan 1 2013

Fingerprint

Androgen Receptors
Prostatic Neoplasms
Androgens
Castration
Ligands
Phenotype
Growth
Prostate
Protein Isoforms
Transcription Factors
Therapeutics
Recurrence
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lonergan, P. E., & Tindall, D. J. (2013). Truncated androgen receptor splice variants in prostate cancer. In Prostate Cancer: Biochemistry, Molecular Biology and Genetics (pp. 351-382). Springer New York. https://doi.org/10.1007/978-1-4614-6828-8_13

Truncated androgen receptor splice variants in prostate cancer. / Lonergan, Peter E.; Tindall, Donald J.

Prostate Cancer: Biochemistry, Molecular Biology and Genetics. Springer New York, 2013. p. 351-382.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lonergan, PE & Tindall, DJ 2013, Truncated androgen receptor splice variants in prostate cancer. in Prostate Cancer: Biochemistry, Molecular Biology and Genetics. Springer New York, pp. 351-382. https://doi.org/10.1007/978-1-4614-6828-8_13
Lonergan PE, Tindall DJ. Truncated androgen receptor splice variants in prostate cancer. In Prostate Cancer: Biochemistry, Molecular Biology and Genetics. Springer New York. 2013. p. 351-382 https://doi.org/10.1007/978-1-4614-6828-8_13
Lonergan, Peter E. ; Tindall, Donald J. / Truncated androgen receptor splice variants in prostate cancer. Prostate Cancer: Biochemistry, Molecular Biology and Genetics. Springer New York, 2013. pp. 351-382
@inbook{6a4f9b1886024905aaa5ccb03e3f3993,
title = "Truncated androgen receptor splice variants in prostate cancer",
abstract = "The androgen receptor (AR) is fundamental for the growth and survival of normal and malignant prostate cells. Therefore, androgen deprivation therapy remains the first-line treatment for disseminated disease; however, relapse and progression to a castration-resistant phenotype for which no durable treatment currently exists, is inevitable. Restored AR activity is fundamental in the progression to castration-resistant prostate cancer. Multiple mechanisms by which AR is reactivated under androgen- depleted conditions may be involved in the development of this lethal phenotype. Recent studies have identified alternatively spliced transcripts encoding truncated AR isoforms that lack the ligand-binding domain, which is the therapeutic target of androgen deprivation therapy. Many of these truncated AR variants function as constitutively active, ligand-independent transcription factors that can support androgenindependent expression of AR target genes, as well as ligand-independent growth of prostate cancer cells. In this chapter, we will summarize the recent developments in the identification and characterization of AR splice variants in prostate cancer.",
author = "Lonergan, {Peter E.} and Tindall, {Donald J.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-6828-8_13",
language = "English (US)",
isbn = "9781461468271",
pages = "351--382",
booktitle = "Prostate Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Truncated androgen receptor splice variants in prostate cancer

AU - Lonergan, Peter E.

AU - Tindall, Donald J.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - The androgen receptor (AR) is fundamental for the growth and survival of normal and malignant prostate cells. Therefore, androgen deprivation therapy remains the first-line treatment for disseminated disease; however, relapse and progression to a castration-resistant phenotype for which no durable treatment currently exists, is inevitable. Restored AR activity is fundamental in the progression to castration-resistant prostate cancer. Multiple mechanisms by which AR is reactivated under androgen- depleted conditions may be involved in the development of this lethal phenotype. Recent studies have identified alternatively spliced transcripts encoding truncated AR isoforms that lack the ligand-binding domain, which is the therapeutic target of androgen deprivation therapy. Many of these truncated AR variants function as constitutively active, ligand-independent transcription factors that can support androgenindependent expression of AR target genes, as well as ligand-independent growth of prostate cancer cells. In this chapter, we will summarize the recent developments in the identification and characterization of AR splice variants in prostate cancer.

AB - The androgen receptor (AR) is fundamental for the growth and survival of normal and malignant prostate cells. Therefore, androgen deprivation therapy remains the first-line treatment for disseminated disease; however, relapse and progression to a castration-resistant phenotype for which no durable treatment currently exists, is inevitable. Restored AR activity is fundamental in the progression to castration-resistant prostate cancer. Multiple mechanisms by which AR is reactivated under androgen- depleted conditions may be involved in the development of this lethal phenotype. Recent studies have identified alternatively spliced transcripts encoding truncated AR isoforms that lack the ligand-binding domain, which is the therapeutic target of androgen deprivation therapy. Many of these truncated AR variants function as constitutively active, ligand-independent transcription factors that can support androgenindependent expression of AR target genes, as well as ligand-independent growth of prostate cancer cells. In this chapter, we will summarize the recent developments in the identification and characterization of AR splice variants in prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=85025473306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025473306&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-6828-8_13

DO - 10.1007/978-1-4614-6828-8_13

M3 - Chapter

AN - SCOPUS:85025473306

SN - 9781461468271

SP - 351

EP - 382

BT - Prostate Cancer

PB - Springer New York

ER -